Skip to main content

MACCD - Multifactor analysis of HPV infected cells in cervical cancer development

Principal investigator

Category
Projekti Hrvatske zaklade za znanost
Project code
IP-2019-04-3403
Finance value
991,000
HRK
Start date
Jan 10th 2020
End date
Jan 9th 2024
Status
Active

Cervical cancer (CC) is the 4th cancer in women worldwide and even in Europe causing ~13,000 deaths annually. Although CC screening and human papillomavirus (HPV) vaccination offer significant protection, each has specific issues. Vaccination is ineffective if administered after HPV exposure, and even if offered according to recommendations, it does not protect against all HPV types causing CC. CC screening programmes, depending on the method used, cytology or HPV testing, have either reduced sensitivity or specificity, respectively, but still have high negative predictive values and effectively reduce mortality. Positive predictive value (PPV) for detecting women at high-risk of CC development, however, remains poor, making them less efficient since large number of women are referred to costly treatments that might not be needed. Besides costs, over-treating women, often of reproductive age, incurs treatment risks as well as complications in pregnancy including miscarriage. With this project, we aim to explore a panel of 30 potentially relevant cellular markers that are likely to correlate with disease course using state-of-the-art mass cytometry profiling. The method allows parallel identification of markers on single cells using a combination of flow cytometry and mass-spectrometry analysis of heavy metal isotope labels. Women with different stages of cervical lesions (n=250) will be enrolled and followed for up to 2 years. Mass cytometry will be done on best representative 100 patients as well as CC and normal cell lines. Resulting data will be correlated with cervical lesion and viral persistence changes. Potential biomarkers will be assessed by immunocytochemistry for validation on all collected samples. Finding biomarkers with high PPV will open the way for improving the efficacy of CC screening and thus significantly alleviate socioeconomic burden of CC as well as lessen the over-treatmetnt risks for future patients.

Other associates

Branka Molnar Stantić, MD

Cytological laboratory Molnar

Ivana Erceg Ivkošić, MD, PhD

Special Hospital St. Catherine

M

G

Magdalena Grce

Dr. , Head of laboratory

Rajko Fureš, MD, PhD

General Hospital Zabok

Tomaš Kalina, MD, PhD

Second Faculty of Medicine, Charles University

This site uses cookies.

Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.